Merck, 315M-95, PD-1 (NAT105) Mouse Monoclonal Antibody

General description
Programmed death-1 (PD-1) is expressed on activated T-cells, B-cells, and myeloid cells. Anti-PD-1 is a marker of angioimmunoblastic lymphoma and suggests a unique cell of origin for this neoplasm. Unlike CD10 and BCL6, PD-1 is expressed by few B-cells, so anti-PD-1 may be a more specific and useful diagnostic marker in angioimmunoblastic lymphoma. In addition, PD-1 expression provides evidence that angioimmunoblastic lymphoma is a neoplasm derived from germinal center-associated T-cells. PD-1 expression in angioimmunoblastic lymphoma lends further support to this model of T-cell oncogenesis, in which specific subtypes of T-cells may undergo neoplastic transformation and result in specific distinct histologic, immunophenotypic, and clinical subtypes of T-cell neoplasia.
Programmed death-1 (PD-1), also known as CD279, is a type-I transmembrane protein expressed on T-cells, B-cells, and monocytes during activation. PD-1 and its ligands (PD-L1 and PD-L2) function as an immune checkpoint pathway by regulating T-cell activation and autoimmunity. PD-1 labels follicular helper T-cells and is therefore a useful marker for angioimmunoblastic T-cell lymphoma.
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Analysis Note

IVD

IVD

IVD

RUO

Other Notes
For Technical Service please contact: 800-665-7284 or email: [email protected]
PD-1 Positive Control Slides, Product No. 315S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany